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Killer cell immunoglobulin-like receptor/HLA class I (KIR/HLA-I) combinations are asso-
ciated with disease risk, implicating functional roles for NK cells (NKCs) or KIR+ T cells.
KIR/HLA-I interactions can act through inhibition of NKC activation by target cells and
NKC licensing for greater intrinsic responsiveness. We compared licensing conferred by
theweaker, HLA-C group 1/KIR2DL3, and the stronger, HLA-C group 2/KIR2DL1, inhibitory
combinations. The “rheostat model” predicts weaker licensing by HLA-C1/KIR2DL3 inter-
actions than HLA-C2/KIR2DL1. We analyzed degranulation in NKC subsets expressing
single and multiple receptors for HLA-I. NKG2A had the strongest licensing impact,
while KIR2DL3, KIR2DL1, and KIR3DL1 were weaker, and not significantly different to
each other. Presence of one or two matched HLA-C allotypes did not alter licensing of
KIR2DL3+ and KIR2DL1+ NKC. Coexpression of activating KIR2DS1 disarmed KIR2DL3+
and KIR2DL1+ NKC to a similar extent. KIR3DL1 and NKG2A combined for more enhanced
licensing of double-positive NKC than the combination of KIR2DL3 and KIR2DL1. Thus,
KIR2DL3 and KIR2DL1 have similar capacity to license NKC, suggesting that inhibitory
signal strength and amount of available HLA-C ligands do not correlate with NKC licens-
ing. Altogether, our results show that the basis for disease associations of HLA-C and
KIR2DL likely encompasses factors other than licensing.
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Introduction
NK-cell (NKC) responses are controlled by signal integration from
a diverse array of germ line-encoded activating and inhibitory
receptors [1]. The inhibitory killer cell immunoglobulin-like
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receptors (KIRs) and the C-type lectin-like receptor, CD94-NKG2A,
bind HLA class I (HLA-I) molecules [2]. These receptors utilize
phosphorylated tyrosines within immunoreceptor tyrosine-based
inhibition motifs (ITIM) in their cytoplasmic tail to recruit tyrosine
phosphatase SHP-1 upon ligand engagement, leading to dominant
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inhibitory signals that block NKC activation [3, 4]. In addition,
inhibitory receptors license NKC, a process whereby functional
interactions between inhibitory receptors on NKC and their lig-
ands confer enhanced responses [5–7]. NKC integrate signals from
activating receptor combinations, which are subject to negative
regulation by dominant inhibitory KIR and NKG2A [8, 9]. Sum-
marized by the “rheostatmodel,” the degree of responsiveness con-
ferred by licensing is tuned according to the number of inhibitory
receptor/HLA-I combinations and the inhibitory signal strength
delivered by each receptor/HLA-I pair [7, 10, 11].
Inhibitory receptor CD94-NKG2A and its ligand HLA-E are
invariant [12, 13], while KIRs and their HLA-I ligands are polymor-
phic [2, 14]. KIR binding is determined mainly by conserved epi-
topes at positions 77 and 80 of HLA-I [2, 15, 16]. KIR2DL2 and 3
bind to the C1 group of HLA-C alleles while KIR2DL1 binds the C2
group [16–18], while KIR3DL1 binds to the Bw4 epitope shared by
many HLA-B alleles [2, 19]. All HLA-C alleles contain either the C1
or C2 epitope while only a fraction of HLA-A and B alleles contain
the Bw4 epitope, leading to the idea that HLA-C function may be
principally in NKC regulation [13, 20]. KIR/HLA-I combinations
are associated with infection, cancer, autoimmunity, and disor-
ders of pregnancy [2, 12, 21]. For example, HLA-C1 and KIR2DL3
homozygosity associated with early resolution of HCV infection
[22]. A favored explanation is “strength of inhibition” [23]: HLA-
C1 and KIR2DL3 have a weaker interaction than KIR2DL1 and C2,
leading to less inhibition and higher NKC responsiveness [2, 24].
The “rheostat model” of licensing predicts that weaker interac-
tions, such as KIR2DL3 and HLA-C1, confer less licensing than
stronger ones, such as KIR2DL1 and HLA-C2. Therefore, it is pos-
sible that the protective association of HLA-C1 and KIR2DL3 with
HCV infection is due to weak licensing and lower NK-cell respon-
siveness. In theory, the protection observed in KIR2DL3–HLA-C1
combinations could result from a reduced inhibition of adaptive
immunity by NKC [25, 26].
We test this hypothesis by studying licensing conferred by
KIR2DL3 and KIR2DL1with different combinations of HLA-C1 and
HLA-C2 haplotypes. We find no significant difference in the capac-
ity of KIR2DL3 and KIR2DL1 to confer NKC licensing. KIR2DL3+
and KIR2DL1+ NK cells (NKCs) were both sensitive to disarming
by the activating receptor KIR2DS1 and combined with KIR3DL1,
and NKG2A, to confer enhanced licensing of double-positive (DP)
NKC to a similar extent.
Results and discussion
NKC licensing by 2DL3 and 2DL1 is not sensitive to
HLA-I ligand number
To test whether KIR2DL3 and KIR2DL1 differ in their capacity
to license NKC, we recruited 29 healthy volunteers and identi-
fied NKC subsets expressing receptors with known roles in licens-
ing: KIR2DL2/S2, KIR2DL3, KIR2DL1, KIR2DS1, KIR3DL1, and
NKG2A (Fig. 1A–C and Supporting Information Fig. 1A). NKC
subsets expressing no receptors (R-ve), a single receptor, or up to
five receptors were determined in the context of KIR genotypes.
The mean percent of each subset is shown in (Supporting Infor-
mation Fig. 1B) and is in line with previous studies [27, 28]. The
KIR2DL2/S2 subset was not studied as KIR2DL2 and KIR2DS2 can-
not be distinguished serologically. To investigate potential impact
of HCMV status on the data in this study, we were able to re-
analyze samples from 19 of our 29 donors; only one had a substan-
tial expansion of CD57+, NKG2C+ NKCs, indicating most donors
were likely not of an HCMV status such as to overtly impact our
detected NKC phenotypes [29] (Supporting Information Fig. 2).
Our healthy donor ethics did not allow us to directly assess HCMV
status.
The responsiveness of each subset was tested by degranula-
tion against K562 targets (Fig. 1D). Receptor negative (R-ve) NKC
and KIR2DS1 single positive cells (KIR2DS1-SP) were unlicensed
and hyporesponsive to activation, whereas NKG2A-SP, KIR2DL3-
SP, KIR2DL1-SP, and KIR3DL1-SP all had enhanced functional
responses compared with receptor negative NKC (Fig. 1E).
Overall, NKG2A conferred the greatest degree of licensing, while
KIR2DL3, KIR2DL1, and KIR3DL1 were weaker (Fig. 1E); some
donors had unlicensed populations due to the absence of the cor-
responding HLA-I ligand (Fig. 1F). For KIR2DL3 and KIR2DL1,
the presence of two HLA-I ligand alleles (C1/C1 or C2/C2)
did not result in greater licensing, in contrast to previous
studies addressing this point [30, 31]. Licensing conferred by
KIR3DL1 was greater in the presence of Bw4/Bw4 as previously
described [32], but was not statistically significant since our donor
pool contained only two genotypically informative donors (Fig.
1F). Thus, HLA-C-specific inhibitory KIRs signal efficiently for
licensing.
KIR2DL3+ and KIR2DL1+ NKC are sensitive to
disarming by KIR2DS1
We next investigated whether KIR2DL1 and KIR2DL3 differed in
relation to other “rheostat model” predictions; “disarming” is a
process whereby NKC responsiveness is reduced due to continu-
ous stimulation by activation receptors [33, 34]. A previous study
showed the activating receptor KIR2DS1, in the presence of an
HLA-C2 ligand, reduced the degree of licensing NKC received
from KIR2DL1 and NKG2A, while licensing by KIR2DL3 appeared
resistant [30]. We compared the ability of KIR2DS1 to “dis-
arm” KIR2DL3+, KIR2DL1+, KIR3DL1+, and NKG2A+ NKCs from
KIR2DS1+ donors carrying C1/C2 and Bw4 haplotypes. Within
each donor, NKC co-expressing KIR2DS1 with a single inhibitory
receptor (KIR2DL3, KIR2DL1, or NKG2A) had lower responsive-
ness by 28, 32, and 30%, respectively, as compared with KIR2DL3-
SP, KIR2DL1-SP, and NKG2A-SP NKC (Fig. 2). Thus, NKC licensed
by KIR2DL3, KIR2DL1, and NKG2A are susceptible to disarming
by KIR2DS1. Compared with previous studies [30], this demon-
strates the impact of KIR2DS1 on KIR2DL3 in C1/C2 individuals—
that is, disarming of licensing through KIR2DL3 in the presence of
KIR2DS1.
C© 2015 The Authors. European Journal of Immunology published by
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Figure 1. Impact of KIR2DL1 and KIR2DL3 on NKC licensing. (A–C) Representative flow cytometry gating strategy for KIR/NKG2A+ NKC from
CD56dim, CD3− lymphocytes in human PBMCs. (A) Identification of KIR2DL3+ and KIR2DL2/S2+ NK cells from a KIR2DL3+/KIR2DL2−/KIR2DS2−
genotype donor (top) and a KIR2DL3+/KIR2DL2+/KIR2DS2+ genotype donor (bottom) with combination of 180 701 and DX27 mAbs. KIRDL2/S2+
cells were excluded from analysis as the mAbs do not distinguish KIR2DL2 and KIR2DS2. Data shown are representative of 16/29 (top) and 12/29
(bottom) individuals, respectively. One individual did not carry KIR2DL3. (B) Identification of KIR2DL1+, KIR2DS1+, and KIR2DL1/S1 double-positive
NKC from a KIR2DL1+/KIR2DS1+ genotype donor (top) and a KIR2DL1+/KIR2DS1− genotype donor (bottom) with combination of 143 211 and 11PB6
mAbs. Data shown are representative of 8/29 (top) and 21/29 (bottom) individuals, respectively. (C) Identification of NKG2A+, KIR3DL1+, and
NKG2A/KIR3DL1 double-positive NKC with combination of DX9 and Z199 mAbs. A total of 29/29 individuals are NKG2A+; 24/29 individuals carried
3DL1; two carried 3DL1 high and 3DL1 low alleles. (D) CD107a (H4A3) expression on CD56dim, CD3− NKC subsets following K562 stimulation. PBMCs
alone (gray-filled histograms) or mixed with K562 at 5:1 in triplicate wells (black-filled histograms, one of three wells are shown). Expression of
CD107a on all combinations of KIR2DL1+, KIR2DL3+, KIR3DL1+, and NKG2A+ NKC from a C1/C1, Bw4/Bw6 KIR2DL2/S2-KIR2DS1 genotype donor.
One triplicate is shown. Filled box indicates receptor positive. (E) Degranulation (CD107a) of NKC subsets expressing single receptors or receptor
negative (R-ve) from 29 healthy volunteers each tested once. Mean CD107a expression from triplicate mixes with K562minus spontaneous CD107a
expression from PBMCs alone. (F) Functional response (CD107a) of KIR2DL3 single positive, KIR2DL1 single positive, and KIR3DL1 single positive
NKC to stimulation with K562 cells in donors with 0, 1, or 2 cognate HLA-I allotypes (from left to right for each KIR). (E and F) Each individual (n =
29) was tested once in triplicate degranulation assays with PBMCs alone to quantify spontaneous expression of CD107a. Each circle shown is the
mean %CD107a+ minus value from PBMCs alone from a single individual with indicated receptor expression. Black lines represent groupmedians.
Data shown are from 29 independent healthy control individuals. Kruskal–Wallis test with Dunn’s multiple comparison test,*p < 0.05; **p < 0.01;
***p < 0.001.
Complementarity of receptor combinations for greater
licensing impact
In line with the “rheostat model,” NKC expressing one, two,
three, and four licensing receptors (KIR2DL3, KIR2DL1, KIR3DL1,
and NKG2A) with their respective ligands, showed progressively
greater responses (Fig. 3A) [11, 28]. DP subsets expressing one
licensed and one unlicensed receptor had the same functional
responsiveness as the licensed SP subset (Supporting Informa-
tion Fig. 3). The greatest increment was between NKC express-
ing one and two receptors; on average SP populations showed
31% CD107a+ degranulation, while DP showed 42% CD107a+
degranulation. However, for a substantial minority (17%) of DP
subsets, there was no enhancement and the functional responsive-
ness was equal to or lower than the greater of the two licensed
SP populations (SP-1; Fig. 3B). These DP subsets across multi-
ple donors included at least one of each of the six combinations
of receptors KIR2DL3, KIR2DL1, KIR3DL1, and NKG2A. For the
DP subsets with greater function than both SP subsets (additive
effect), we calculated the difference (CD107a+) between these
DP subsets and their respective single positive populations. As
there are two SP populations for each DP, each SP value was
C© 2015 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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Figure 2. KIR2DL3+ and KIR2DL1+ NKC are sensitive to disarming by
KIR2DS1. Functional response (CD107a) of indicated single receptor
positive NKC subsets (SP) to K562 stimulation was compared with
subsets co-expressing the single inhibitory receptor with KIR2DS1.
Seven healthy volunteer donors carried KIR2DS1, and all were C1/C2,
Bw4+. Each circle is from one donor with indicated receptor expres-
sion. Connected lines indicate populations from the same donor. Seven
healthy control individuals carried KIR2DS1 and HLA-C2, and were also
C1+/Bw4+. Each circle shown is themean%CD107a+minus value from
PBMCs alone from a single individual with indicated receptor expres-
sion. Wilcoxon signed rank test (two-tailed), *p < 0.05.
deducted from the DP value separately and the mean of the
two resulting values was used. The weakest complementarity was
between KIR2DL3 and KIR2DL1, with an average of 9% enhanced
degranulation, compared with the average of the degranulation
observed with KIR2DL3-SP and KIR2DL1-SP NKC (Fig. 3C). The
receptor combination showing greatest complementarity in pro-
moting licensing was KIR3DL1 and NKG2A, with an average of
17% enhanced degranulation compared with the average of the
degranulation observed with KIR3DL1-SP and NKG2A-SP NKC.
The additive effect of receptor combinations for greater licensing
impact increased incrementally, from the lowest with receptors
specific for HLA-C1 and HLA-C2, to HLA-C1 or C2 with HLA-B,
HLA-C1 or C2 with HLA-E, and the highest with HLA-B and HLA-E,
suggesting that receptors with more divergent HLA-I specificities
are more complementary for overall licensing impact. This con-
cept of additive education is in keeping with earlier studies [28,
35, 36].
Concluding remarks
Associations of KIR2DL and HLA-C with disease have generally
been interpreted with respect to “strength of inhibition” [23].
For example, the protective combination of HLA-C1 and KIR2DL3
in clearing HCV infection could be due to the weaker binding
of KIR2DL3 to HLA-C than that of KIR2DL1 or KIR2DL2 [22].
We tested whether such associations might be explained by dif-
ferences in impact on NKC licensing. Our data are consistent
with the “rheostat model,” demonstrating the disarming role of
activating receptor KIR2DS1 and the greater licensing impact
of inhibitory receptor combinations. In addition, KIR2DL3 and
KIR2DL1 were similar in their capacity to license NKC and to com-
plement KIR3DL1 or NKG2A for enhanced licensing. These results
suggest that inhibitory signaling by KIR2DL3 bound to HLA-C lig-
ands may be as strong as signaling by other KIR–HLA-C combina-
tions, or that signaling by KIR2DL3 is sufficiently strong to result
in similar licensing impact. It is possible that inhibitory KIR recep-
tors may differ in their capacity to recognize changes in peptide
repertoire. Indeed, it was recently suggested that KIR2DL2 and
KIR2DL3 differ in their peptide selectivity for HLA-C1 [37].
Figure 3. KIR3DL1 and NKG2A combine for greater additive licensing impact than KIR2DL3 and KIR2DL1. (A) Degranulation (CD107a) of NKC
subsets expressing 1, 2, 3, or 4 licensing receptors (KIR2DL3, KIR2DL1, KIR3DL1, and NKG2A), from 29 volunteers, previously defined as licensed
due to the presence of their respective ligands. (B) Functional responsiveness of double-positive (DP) NKC were additive (right) or had no effect
(left) compared with contributing single positive (SP) subsets (SP-1 and SP-2). SP-1 had greater function of each pair, regardless of receptor identity.
No effect was defined as CD107a(DP)  (SP-1), additive as CD107a(DP) > (SP-1). Connected lines indicate populations from the same donor. (C)
Net degranulation of DP NK subsets defined as additive in Figure 3B stratified by all six combinations of KIR2DL3, KIR2DL1, KIR3DL1, and NKG2A.
Degranulation of each SP subset (SP-1 and SP-2) was deducted from each DP subset separately, resulting in two values of which the mean was
taken and plotted. Black line = median for each group. Each circle shows one donor with indicated receptor expression, horizontal black lines
show median values for each group. Data are from all 29 healthy volunteers. Each circle shown is one individual with mean %CD107a+ from
triplicate degranulation assays minus value from PBMCs alone from a single individual with indicated receptor expression. Data shown are from
29 independent healthy control individuals. Kruskal–Wallis test with Dunn’s multiple comparison test,*p < 0.05; **p < 0.01; ***p < 0.001, n.s: not
significant.
C© 2015 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
Eur. J. Immunol. 2015. 00: 1–7 Innate immunity 5
Materials and methods
Human donors and ethical approval
All studies were conducted according to the principles expressed
in the Declaration of Helsinki. Healthy volunteers were recruited
with informed consent with ethical approval through the
Imperial College Human Tissue Bank, London (REC number
12/WA/0196).
PBMC isolation and cell culture
PBMCs were isolated from 20–30 mL peripheral blood by den-
sity centrifugation over Histopaque (Sigma, UK) using SepMate
(STEMCELL Technologies, France) tubes and cultured in RPMI
(GIBCO, Life Technologies, UK), 10% FCS (Labtech, UK). K562
cells were cultured in RPMI, and 10% FCS supplemented with glu-
tamine, penicillin, and streptomycin (GIBCO, Life Technologies).
KIR and HLA genotyping
Genomic DNA was isolated from peripheral blood by high salt
extraction. KIR genotyping was performed using SSP-PCR (Mil-
tenyi Biotec, UK, 130-092-584). HLA-A, B, and C loci were typed
by SSOP PCR.
Identification of NK subsets
Freshly isolated PBMCs (106)were stained with fluorochrome con-
jugated mAbs (CD3, CD56, KIR2DL1, KIR2DL3, KIR2DL2/L3/S2,
NKG2A, KIR3DL1, and KIR2DL1/S1-biotin) for 30min at 4°C, then
streptavidin-APC-eF780 for 30 min at 4°C. Cells were acquired on
an FACs Aria II (BD Biosciences, USA). CD56dim, CD3− NKCs were
identified from single cells in the lymphocyte gate. Receptor posi-
tive populations in the CD56dim gate were first gated for presence
of KIR2DL2/S2 and KIR2DL3, then KIR2DL1 and KIR2DS1, then
KIR3DL1 and NKG2A (Fig. 1A–C). Sequential gating for the pres-
ence or absence of each receptor allowed the identification of
NKC subsets expressing up to five receptors and a maximum of
48 different subsets. Frequency of subsets was determined by the
number of events in each subset as a proportion of the total events
for CD56dim, CD3− NKC. Unexpected staining patterns with 11PB6
mAb, likely due to the KIR2DL3*005 allele [38], were found in
two donors and excluded from analysis.
NK-cell degranulation assay
Freshly isolated PBMCs (106) were mixed with K562 target cells
at 5:1 for 2 h in the presence of anti-CD107a-BV421 antibody.
NKC subsets were identified as above by flow cytometry. Exper-
iments were carried out in triplicate with a no target control to
assess spontaneous degranulation (CD107a), the value of which
was subtracted from values obtained from cell mixes. Data were
analyzed using FlowJo software (v10.07, Treestar Inc., USA).
Monoclonal antibodies
APC-KIR3DL1(DX9), Biotin-KIR2DL1/S1(11PB6), PERCP-KIR2
DL2/L3/S2(DX27) fromMiltenyi Biotec. FITC-KIR2DL3(180701),
PE-KIR2DL1(143211), Alexa-flour488-NKG2C(FAB138G) from
R&D systems, UK. PE-Cy7-NKG2A(Z199) from Beckman Coul-
ter, UK. BV421-CD107a(H4A3), BV510-CD3(UCHT1), BV605-
CD56(NCAM16.2) from BD Biosciences, UK. Alexa-flour647-
CD57(HCD57) from Biolegend, UK.
Statistical analysis
Statistical analysis was performed using GraphPad Prism V5.0. For
comparisons of multiple groups, Kruskal–Wallis test with Dunn’s
multiple comparison test was used. For comparisons of two groups
of paired observations, Wilcoxon signed rank test (two-tailed) was
used. p Values of <0.05 were considered significant.
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